Stem Cell Development Services for Brain Tumors

Stem cell research has emerged as a cornerstone in the study of brain tumors, providing critical insights into tumor biology, progression, and therapeutic resistance. The unique properties of stem cells, including their ability to self-renew and differentiate, make them ideal models for understanding the complexities of brain tumors such as glioblastoma and medulloblastoma. Alfa Cytology specializes in stem cell development services tailored for brain tumor research.

Introduction to Brain Tumor Stem Cell Models

Brain tumors, particularly gliomas, represent some of the most challenging malignancies to treat, largely due to their complex biology and the presence of cancer stem cells (CSCs). Among these, glioma stem cells (GSCs) have garnered significant attention for their role in tumor initiation, progression, and recurrence. Understanding and modeling GSCs are crucial for developing effective therapeutic strategies.

Fig.1 Characterization of glioma stem cells. (Piper K., et al., 2021)

Stem cell models are essential for dissecting the unique characteristics of GSCs. These models allow us to study the self-renewal capabilities, differentiation potential, and tumorigenicity of GSCs in vitro and in vivo. By mimicking the tumor microenvironment, these models provide insights into how GSCs interact with surrounding cells and respond to therapies.

Applications of Brain Tumor Stem Cell Models

Drug Testing and Development

Understanding Mechanisms of Resistance

Biomarker Discovery

Our Services

Alfa Cytology offers a comprehensive suite of services focused on stem cell development for brain tumors. Our commitment to precision and innovation allows us to provide high-quality stem cell models that facilitate advanced studies in cancer biology and therapy.

Isolation and Characterization of Tumor-Derived Stem Cells
Using techniques such as fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS), Alfa Cytology enriches for stem cell populations. Each isolated stem cell line undergoes extensive characterization to confirm stemness markers, differentiation potential, and genetic stability, ensuring that the cells accurately represent the original tumor.
Stem Cell Culture and Expansion
Alfa Cytology utilizes serum-free media and specific growth factors to promote the proliferation of stem cells while maintaining their undifferentiated state.
Functional Assays and Drug Testing
Alfa Cytology provides a range of functional assays to investigate the biological behavior of developed stem cell lines.
- Proliferation and Migration Assays
- Drug Response Studies

Workflow of Our Service

Alfa Cytology obtained CD133⁺ cells from tumor tissues and cultured them in serum-free DMEM/F12 medium containing basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) to form tumor spheres that grew in suspension. The tumor spheres were isolated with CD133 immunomagnetic beads to obtain CD133⁺ monocytes. And the cells were inoculated and cultured at a certain concentration. The expression rate of markers, cell proliferation cycle, and ploidy changes were also detected by flow cytometry.

Cell Preparation

Culture to Form Tumor Spheres

Isolation Culture

Primary BTSCs and Recurrent BTSCs

Marker Detection and Observation

Case Study - CD133+ Glioblastoma Stem Cell Xenograft Model

Model Introduction

The CD133+ glioblastoma (GMB) stem cell xenograft model provides a validated preclinical platform for studying tumor-initiating cells and their interaction with mesenchymal stem cells (MSCs) in glioblastoma progression. CD133+ GBM cells, isolated from primary human glioblastoma samples via neurosphere formation, represent the tumor-initiating subpopulation responsible for tumor maintenance and therapeutic resistance.

Model Information

Model: CD133+ GBM Stem Cell Xenograft Model
Animals: Immunosuppressed Wistar Rats
Age: 7 Weeks

Cancer Type: Glioblastoma
Weight: 180-220 g

Model Construction

The model was established by stereotaxic implantation of CD133+ GBM cells (1×10⁴ cells/animal) into the right caudate putamen of immunosuppressed rats. Tumor growth and MSC migration were monitored by fluorescence imaging, MRI, and histological analysis.

Fig. 2 Workflow of CD133+ GBM stem cell xenograft model establishment. (Source: Alfa Cytology)

Model Data

Tumorigenicity: CD133+ GBM cells demonstrate high tumorigenic potential, generating tumors with high cellularity, nuclear atypia, and invasiveness by day 28 post-implantation.
Therapeutic Window: Tumor establishment requires approximately 28 days post-implantation. MSC infusion at day 28 allows observation of migration and tumor promotion over a 20-day period.
Therapeutic Efficacy: Drug A treatment (40 mg/kg, oral, daily) significantly reduces MSC-promoted tumor progression, decreasing tumor volume, proliferation, and microvascular density, while extending median survival, demonstrating the model's utility for evaluating TAM-targeted therapies.

Fig. 3 Drug A treatment abrogates MSC-promoted tumor progression in CD133+ GBM stem cell xenograft model. Data are expressed as mean ± SEM. (Source: Alfa Cytology)

Contact Us

For researchers aiming to advance their studies on brain tumors through innovative stem cell models, Alfa Cytology is committed to providing exceptional development services. Our team of experts is ready to assist you at every step of your research journey. To learn more about our services or to discuss your specific needs, please feel free to contact to communicate project details.

Reference

Piper K., et al. (2021). Glioma stem cells as immunotherapeutic targets: advancements and challenges[J]. Frontiers in Oncology. 11: 615704.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.